ENVERIC BIOSCIENCES INC
ENVBNASDAQ🏆 #4957 by market capUS Equity
$1.43▲ $0.06 (+4.38%)
Market closed · at closeTrack ENVB
Get earnings, price moves & breaking news on Telegram
24h▲ 4.4%
7d▼ 4.0%
14d▲ 2.1%
30d▼ 3.1%
ytd▼ 62.6%
1y▼ 78.8%
🏦Market Cap
$6M
Small Cap
📈Revenue Growth (YoY)
-7.2%
Declining
📊Gross Margin
20.4%
Moderate
💵FCF Margin
0.4%
Thin
⚖️P/S Ratio
0.2x
Cheap
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $1.36 – $1.43
- 52-Week Range
- $1.17 – $13.25
- Volume (shares)
- 1,061
- Avg Volume (shares)
- —
- Shares Outstanding
- 4.5M
- Next Earnings
- —
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- 0.2x
- EPS (TTM)
- $-11.15
- Dividend Yield
- —
- Dilution (1yr)
- +1845.0%
ENVERIC BIOSCIENCES INC
ENVBFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$9M▼ −8.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$8M▲ +5.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
1.1M▲ +1845.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$5M▲ +$2M YoY
StockOtter · stockotter.spaceAbout ENVERIC BIOSCIENCES INC
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst Ratings
ⓘConsensus
Buy
7 analysts
Strong Buy2
Buy4
Hold1
Sell0
Strong Sell0
Ratings as of Feb 2026
Latest News & Updates
News unavailable.